Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer

Prostate

Volumn 74, Issue 6, 2014, Pages 659-668

  Eder, Matthias ^a   Schäfer, Martin ^a   Bauder Wüst, Ulrike ^a   Haberkorn, Uwe ^b   Eisenhut, Michael ^a   Kopka, Klaus ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

bispecific PET imaging; heterodimeric radiopharmaceuticals; prostate cancer; tumor heterogeneity

Indexed keywords

GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; HETERODIMER; NONAPEPTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL SURFACE; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PEPTIDE SYNTHESIS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN SYNTHESIS; RAT;

BISPECIFIC PET IMAGING; HETERODIMERIC RADIOPHARMACEUTICALS; PROSTATE CANCER; TUMOR HETEROGENEITY;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 84897021830     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22784     Document Type: Article

References (29)

1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM,. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40 (4): 486-495.
2. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM,. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39 (6): 1085-1086.
3. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW,. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013; 54 (8): 1369-1376.
4. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, Armor T, Stubbs JB, Maresca KP, Stabin MG, Joyal JL, Eckelman WC, Babich JW,. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013; 54 (3): 380-387.
5. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA,. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38 (5): 696-701.
6. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-85.
7. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82 (11): 2256-2261.
8. Marusyk A, Polyak K,. Tumor heterogeneity: Causes and consequences. Biochim Biophys Acta 2010; 1805 (1): 105-117.
9. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15 (2): 167-172.
10. Markwalder R, Reubi JC,. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999; 59 (5): 1152-1159.
11. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ,. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009; 69 (10): 1101-1108.
12. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Muntener M, Kristiansen G,. Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate 2012; 72 (3): 318-325.
13. Yu Z, Ananias HJ, Carlucci G, Hoving HD, Helfrich W, Dierckx RA, Wang F, de Jong IJ, Elsinga PH,. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des 2013; 19 (18): 3329-3341.
14. Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M,. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005; 46 (4): 691-699.
15. Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG,. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008; 51 (24): 7933-7943.
16. Schuhmacher J, Maier-Borst W,. A new Ge-68/Ga-68 radioisotope generator system for production of Ga-68 in dilute HCl. Int J Appl Radiat Isot 1981; 32: 31-36.
17. Eder M, Schäfer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M,. (68)Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23 (4): 688-697.
18. Eder M, Wangler B, Knackmuss S, Legall F, Little M, Haberkorn U, Mier W, Eisenhut M,. Tetrafluorophenolate of HBED-CC: A versatile conjugation agent for (68)Ga-labeled small recombinant antibodies. Eur J Nucl Med Mol Imaging 2008; 35 (10): 1878-1886.
19. Schäfer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M,. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2012; 2 (1): 23.
20. Liu Z, Yan Y, Liu S, Wang F, Chen X,. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009; 20 (5): 1016-1025.
21. Liu Z, Yan Y, Chin FT, Wang F, Chen X,. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009; 52 (2): 425-432.
22. Liu Z, Niu G, Wang F, Chen X,. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009; 36 (9): 1483-1494.
23. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X,. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009; 50 (7): 1168-1177.
24. Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M,. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 2004; 19 (2): 173-180.
25. Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M,. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004; 45 (10): 1716-1720.
26. Eder M, Eisenhut M, Babich J, Haberkorn U,. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40 (6): 819-823.
27. Liu Z, Huang J, Dong C, Cui L, Jin X, Jia B, Zhu Z, Li F, Wang F,. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma. Mol Pharm 2012; 9 (5): 1409-1417.
28. Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ,. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: A heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol 2012; 39 (3): 377-387.
29. Liu T, Toriyabe Y, Kazak M, Berkman CE,. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 2008; 47 (48): 12658-12660.